Organon & Co. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
Organon & Co. (OGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $8.11 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-07-31
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2026-03-31 was $8.36, a 14.08% decline year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2025-03-31 was $9.73, a 17.65% increase year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2024-03-31 was $8.27, a 4.94% decline year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2023-03-31 was $8.70.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2025 was $4.33, a 43.47% decline from fiscal 2024.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2024 was $7.66, a 21.11% decline from fiscal 2023.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2023 was $9.71, a 2.53% increase from fiscal 2022.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2022 was $9.47.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 4 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 7 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8.11 10-Q · filed 2026-07-31 | |||||
| 2026-03-31 | $8.36 10-Q · filed 2026-05-04 | |||||
| 2025-12-31 | $4.33 10-K · filed 2026-02-24 | |||||
| 2025-09-30 | $6.63 10-Q · filed 2025-11-10 | |||||
| 2025-06-30 | $6.63 10-Q · filed 2025-08-06 | |||||
| 2025-03-31 | $9.73 10-Q · filed 2025-05-02 | |||||
| 2024-12-31 | $7.66 10-K/A · filed 2025-11-10 | |||||
| 2024-09-30 | $7.66 10-Q · filed 2024-11-01 | |||||
| 2024-06-30 | $7.57 10-Q · filed 2024-08-07 | |||||
| 2024-03-31 | $8.27 10-Q · filed 2024-05-03 | |||||
| 2023-12-31 | $9.71 10-K · filed 2024-02-26 | |||||
| 2023-09-30 | $8.70 10-Q · filed 2023-11-03 | |||||
| 2023-06-30 | $8.70 10-Q · filed 2023-08-09 | |||||
| 2023-03-31 | $8.70 10-Q · filed 2023-05-05 | |||||
| 2022-12-31 | $9.47 10-K · filed 2023-02-27 | |||||
| 2022-09-30 | $9.70 10-Q · filed 2022-11-04 | |||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-05 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | |||||
| 2021-12-31 | $9.05 10-K · filed 2022-03-21 | |||||
| 2021-09-30 | $9.11 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |